- Home
- SVRA vs INBX Comparison
SVRA vs INBX Comparison
Compare SVRA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- INBX
- Stock Information
- Founded
- SVRA 2007
- INBX 2010
- Country
- SVRA United States
- INBX United States
- Employees
- SVRA N/A
- INBX N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- INBX Health Care
- Exchange
- SVRA Nasdaq
- INBX Nasdaq
- Market Cap
- SVRA 527.2M
- INBX 430.2M
- IPO Year
- SVRA N/A
- INBX 2020
- Fundamental
- Price
- SVRA $3.95
- INBX $80.89
- Analyst Decision
- SVRA Buy
- INBX Hold
- Analyst Count
- SVRA 8
- INBX 2
- Target Price
- SVRA $6.88
- INBX N/A
- AVG Volume (30 Days)
- SVRA 1.7M
- INBX 724.3K
- Earning Date
- SVRA 11-13-2025
- INBX 11-14-2025
- Dividend Yield
- SVRA N/A
- INBX N/A
- EPS Growth
- SVRA N/A
- INBX N/A
- EPS
- SVRA N/A
- INBX N/A
- Revenue
- SVRA N/A
- INBX $1,400,000.00
- Revenue This Year
- SVRA N/A
- INBX $563.00
- Revenue Next Year
- SVRA N/A
- INBX $230.77
- P/E Ratio
- SVRA N/A
- INBX N/A
- Revenue Growth
- SVRA N/A
- INBX N/A
- 52 Week Low
- SVRA $1.89
- INBX $10.81
- 52 Week High
- SVRA $4.51
- INBX $86.64
- Technical
- Relative Strength Index (RSI)
- SVRA 50.44
- INBX 82.88
- Support Level
- SVRA $4.14
- INBX $71.00
- Resistance Level
- SVRA $4.51
- INBX $86.62
- Average True Range (ATR)
- SVRA 0.22
- INBX 7.97
- MACD
- SVRA -0.05
- INBX 2.27
- Stochastic Oscillator
- SVRA 11.63
- INBX 90.73
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.